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ABSTRACT
First-line nilotinib in chronic myeloid leukemia is more effective than imatinib 
to achieve early and deep molecular responses, despite poor tolerability or failure 
observed in one-third of patients. The toxicity and efficacy of tyrosine kinase 
inhibitors might depend on the activity of transmembrane transporters. However, 
the impact of transporters genes polymorphisms in nilotinib setting is still debated. 
We investigated the possible correlation between single nucleotide polymorphisms 
of hOCT1 (rs683369 [c.480C>G]) and ABCB1 (rs1128503 [c.1236C>T], rs2032582 
[c.2677G>T/A], rs1045642 [c.3435C>T]) and nilotinib efficacy and toxicity in a 
cohort of 78 patients affected by chronic myeloid leukemia in the context of current 
clinical practice. The early molecular response was achieved by 81% of patients 
while 64% of them attained deep molecular response (median time, 26 months). 
The 36-month event-free survival was 86%, whereas 58% of patients experienced 
toxicities. Interestingly, hOCT1 and ABCB1 polymorphisms alone or in combination 
did not influence event-free survival or the adverse events rate. Therefore, in contrast 
to data obtained in patients treated with imatinib, hOCT1 and ABCB1 polymorphisms 
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do not impact on nilotinib efficacy or toxicity. This could be relevant in the choice of 
the first-line therapy: patients with polymorphisms that negatively condition imatinib 
efficacy might thus receive nilotinib as first-line therapy.
INTRODUCTION
After the introduction in the clinical practice of the 
tyrosine kinase inhibitors (TKIs), the outcome of patients 
affected by chronic myeloid leukemia (CML) has really 
improved, with 96% of them alive and free of progression 
at 3 years [1].
Nilotinib was initially approved as a second-
generation TKI for the treatment of patients resistant to 
imatinib, and since 2007 also as a first-line option [2]. It 
is structurally similar to imatinib, binding to the inactive 
conformation of the protein encoded by the BCR-ABL1 
fusion gene, but it is also characterized by a higher 
efficacy than imatinib [3]. The prospective, randomized 
phase-3 trial ENESTnd comparing nilotinib 300 mg 
or 400 mg twice/day vs imatinib 400 mg daily clearly 
demonstrated the superiority of nilotinib in terms of 
complete cytogenetic response (CCyR) (by 12 months, 
80% in the nilotinib vs 65% in the imatinib arm) and of 
major molecular response (MR3) (by 5 years, 77% for 
nilotinib vs 60.4% for imatinib, p<0.0001). Interestingly, 
progressions occurred in 5 out of the 563 patients in the 
nilotinib arms (0.88%) in comparison to 12 out of 283 
cases receiving imatinib (4.2%) [4].
Overall, the choice of nilotinib as first-line treatment 
significantly increases the probability of reaching the 
desired surrogate end-points at the correct time-points, 
but also the probability of achieving a deep molecular 
response (DMR, by 5 years, 54% with nilotinib vs 31% 
for imatinib), which represents the basis for a further 
possible drug discontinuation. Nevertheless, about 40% of 
patients discontinue nilotinib due to suboptimal response 
or toxicity [4].
Different mechanisms have been recognized on 
the basis of TKI resistance, from the ABL1 mutations [5] 
to the activation of several alternative pro-proliferative 
pathways (such as Wnt, PI3K, Aurora Kinase, STAT3) [6-
8] or the inhibition of the correct immunological control 
[9]. In addition, the transmembrane transporters have 
been also indicated as responsible for the resistance to 
TKIs, with a relevant role recognized to the ATP binding 
cassette (ABC) efflux pumps and to the human organic 
cation transport member 1 (hOCT1) influx protein [10]. 
Indeed, the pharmacokinetics and pharmacodynamics of 
imatinib seem to be influenced by ABCB1 [11-13], hOCT1 
[14-16], and ABCG2 polymorphisms [17]. Moreover, an in 
vitro study conducted on resistant K562 cells showed that 
ABCG2 over-expression was associated with a reduced 
efficacy of imatinib, nilotinib, dasatinib, and bosutinib 
[18]. On the contrary, other studies demonstrated that 
dasatinib is a substrate of ABCB1 [19], while the binding 
affinity of this transmembrane transporter seems to be 
lower for nilotinib [20, 21], bosutinib [22], and ponatinib 
[21]. Moreover, nilotinib appeared as one of the most 
potent modulators of ABCB1 and ABCG2 in respect of 
imatinib, dasatinib, erlotinib, lapatinib, and sunitinib in a 
murine model of chemoresistance [23].
Finally, a recent meta-analysis clearly demonstrated 
that the highest values of minimum plasma concentrations 
of imatinib were significantly correlated with the complete 
cytogenetic response, but not with the achievement of the 
complete molecular response [13]. About polymorphisms, 
authors concluded that the c.421A ABCG2 variant allele 
was significantly associated with higher rate of MR3, 
whereas ABCB1 variant alleles did not, with the exception 
of c.2677T/A alleles [13]. However, the complexity of 
the methods used for data analyses and the different non-
comparable models have frequently led to conflicting 
results [24, 25].
With these premises, we decided to address the 
influence of ABCB1 and hOCT1 polymorphisms on the 
response rate and toxicity of first-line nilotinib in the 
context of a multicenter “real-life” series of 78 CML 
cases. Of note, patients were enrolled in a prospective and 
retrospective way in order to perform the analyses in a 
powered study.
RESULTS
Nilotinib efficacy: hematological, cytogenetic, 
molecular responses, and EFS
Seventy-eight CML patients, all in chronic phase, 
median age 47 years (range, 18-79) were enrolled in the 
study. Forty-six (59%) were males, and 32 (41%) were 
females. According to the Sokal, Hasford, and European 
Treatment and Outcome Study (EUTOS) scores, nearly 
half of the patients were classified into the low-risk 
groups. The median follow-up time in our study was 
43 months; 2/3 of the enrolled cases were followed for 
36 months, 74% for 24 months, 80% for 18 months. All 
patients had a minimum follow-up of 12 months. No 
significant differences in clinical characteristics have 
been observed between the prospective and retrospective 
cohorts (Table 1). The response rates have been detailed 
in Table 2.
Hematological response
Seventy-six out of the 78 patients enrolled into 
the study (97.4%) achieved a complete hematological 
response (CHR) by 3 months of treatment; the remaining 
two subjects reached a complete response by the sixth 
month of therapy. Overall, the CHR rate in our series was 
100%.
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Cytogenetic response
Sixty-nine patients (88.5%) achieved a complete 
cytogenetic response (CCyR) by 12 months, with 66 
cases (84.6%) reaching a CCyR already by the sixth 
month [the time point identified as “optimal” by the 
European Leukemia Net (ELN) guidelines] [26]. The 
median time to achieve a CCyR was 3.2 months (range, 
1.8-14.4); interestingly, by the 18th month of treatment, 
the Philadelphia chromosome disappeared in 77 out of 78 
patients. With a median follow-up of 43 months (range 
4-106), no cases of loss of CCyR have been reported. The 
CCyR achievement was not significantly conditioned by 
sex, age, or Sokal and EUTOS score; nevertheless, the 
high Hasford score was associated with a lower probability 
of reaching the CCyR by the 12th month with respect to 
the other groups (11% vs 43%; p=0.01). No significant 
differences in the quality of cytogenetic response were 
observed between the prospective and retrospective cohort.
Molecular responses
overall, the early molecular response (EMR) was 
achieved by 63 patients (81%); then, 68 subjects (87%) 
achieved an MR3 during the treatment. Of note, 60 
patients reached an MR3 by 12 months, which identifies 
the optimal response. Furthermore, patients who 
experienced EMR more frequently achieved an MR3 by 
the 12th month (83.6% vs 38.5%; p=0.002). The median 
time to achieve an MR3 was 6.1 months (range, 2.6 - 83); 
this interval was 7 months longer for cases without EMR. 
Seven patients (9%) lost the MR3 during treatment, with 
a median time of 31.2 months. As reported in Table 2, 
the EMR rate was higher in the prospective than in the 
retrospective cohort (p=0.012).
The 64.1% of patients receiving nilotinib achieved 
a DMR (≥MR4), with a median time to DMR attainment 
of 26 months: in particular, 24.3%, 28.2% and 11.5% of 
patients achieved an MR4, MR4.5 and MR5, respectively. 
As above reported for the MR3, also the DMR was 
more frequently achieved by subjects in EMR (71.8% 
vs 35.8%; p=0.04). As reported in Table 2, the DMR rate 
was higher in the retrospective than in the prospective 
cohort (p=0.002). The molecular response rates were not 
significantly conditioned by age, sex or CML risk scores.
EFS
All patients were still alive in July 2016. Thus, 
only the event-free survival (EFS) was considered for 
the statistical analysis. The 24-months EFS for the whole 
series was 89%, while the EFS at 36 and 48 months was 
86% and 81%, respectively. Age >60 years, sex, and CML 
Table 1: Clinical characteristics of the 78 enrolled patients
Clinical feature Overall series n. (%) Prospective cohort 
n. (%)
Retrospective cohort 
n. (%)
Statistical 
significance*
Patients 78 29 49
Age (years)** 47 (18-79) 49 (20-68) 46 (18-79) p=0.460
Sex p=0.351
 M 46 (59%) 15 (52%) 31 (63%)
 F 32 (41%) 14 (48%) 18 (27%)
Sokal risk score p=0.542
 Low 34 (44%) 11 (38%) 23 (47%)
 Intermediate 29 (37%) 12 (42%) 17 (34%)
 High 15 (19%) 6 (20%) 9 (19%)
Eutos risk score p=0.301
 Low 40 (51%) 11 (38%) 29 (59%)
 High 27 (35%) 11 (38%) 16 (33%)
 N/A 11 (14%) 7 (24%) 4 (8%)
Hasford risk score p=0.054
 Low 40 (51%) 11 (38%) 29 (59%)
 Intermediate 26 (34%) 14 (48%) 12 (25%)
 High 12 (15%) 4 (14%) 8 (16%)
Note: *, Students’ t test; **, values are expressed as median (min-max range)
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risk scores did not significantly impact on EFS. Similarly, 
the achievement of CCyR (either by 6 or by 12 months) 
did not significantly impact on EFS. On the contrary, the 
probability of proceeding without events was significantly 
higher for patients in EMR (94.5% vs 74.5% at 24 months; 
86.2% vs 67.8% at 48 months; p=0.021) and for those who 
achieved a DMR during treatment (91% vs 84% at 24 
months; 84% vs 70% at 48 months; p=0.020) (Figure 1). It 
is worth noting that the two groups of patients differed for 
EMR and DMR rates (Table 1) but not in terms of EUTOS 
and Sokal scores (Table 2). Therefore, it is plausible that 
the observed differences between groups could be mainly 
related to the limited number of patients enrolled.
Moreover, because in these cohorts only one event/
each was censored, we analyzed the EFS in the whole 
series. When EMR and DMR were considered in the 
multivariate analysis, both lost the respective statistical 
significance. No differences in EFS according to the time 
to MR3 or DMR were observed.
Nilotinib toxicity
Overall, 45 patients (57.7%) developed toxicities: in 
particular, 10 (22.2%) suffered from hematological and 35 
(77.8%) from extra-hematological adverse events (AEs); 5 
cases reported both hematological and extra-hematological 
toxicities. AEs are listed in Table 3.
Among the extra-hematological toxicities, 30% 
interested the skin (more frequently rashes and dry 
skin), and 25% pancreas and liver (amylase, lipase, 
bilirubin and transaminases increased values). Other 
recorded AEs were metabolic (17.5%) (hyperglycemia, 
hypercholesterolemia), vascular (8%) (two cases of 
peripheral arterial occlusive disease, one of myocardial 
ischemia, two case of hypertension, one of arrhythmia), 
neurological (10%) (headache), and ocular (5%) 
(conjunctivitis) events.
In all cases the hematological toxicities were of 
grade 1 and 2; the extra-hematological adverse events 
Table 2: Hematological, cytogenetic, and molecular responses at different time-points
Responses Overall Series n. (%) Prospective cohort 
n. (%)
Retrospective cohort 
n. (%)
Statistical 
significance
CHR by 3 months
 Yes 76 (97%) 29 (100%) 47 (96%) p=0.392
 No 2 (3%) 0 2 (4%)
CCyR by 6 months
 Yes 66 (85%) 25 (86%) 41 (84%) p=0.376
 No 12 (15%) 4 (14%) 8 (16%)
CCyR by 12 months
 Yes 69 (88.5) 25 (86%) 44 (90%) p=0.593
 No 9 (11.5) 4 (14%) 5 (10%)
EMR
 Yes 63 (81%) 28 (96%) 35 (71%) p=0.012
 No 15 (19%) 1 (4%) 14 (29%)
MR3 by 12 months
 Yes 60 (77%) 22 (76%) 38 (78%) p=0.537
 No 18 (23%) 7 (24%) 11 (22%)
MR3 (at any time)
 Yes 68 (88%) 23 (79%) 45 (92%) p=0.182
 No 10 (12%) 6 (21%) 4 (8%)
DMR (at any time)
 Yes 50 (64%) 13 (45%) 37 (76%) p=0.002
 No 28 (36%) 16 (55%) 12 (24%)
Abbreviations: CHR, complete hematological response; CCyR, complete cytogenetic response; EMR, early molecular 
response; MR3, complete hematological response; DMR, deep molecular response
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were of grade 1 and 2 in the 48.6%. Only in 2 cases 
toxicity was of grade 4 (one patient with hepatic toxicity, 
another one with cutaneous toxicity); in the remaining 16 
cases (45.7%), the AEs were of grade 3.
All cases of hematological toxicity occurred in the 
first year of therapy, with a median time of 1.3 months 
(range, 1-12); similarly, 80% of the extra-hematological 
AEs presented in the first year of treatment, but with a 
median time of 7.5 months (range, 0.2-85).
It is worth noting that the occurrence of AEs had a 
significant impact on the drug administration: half of the 
patients reduced the dose at least once during the follow-
Figure 1: The probability of event-free survival (EFS) of the whole series according to the achievement of early molecular response 
(EMR, (A)) and deep molecular response (DMR, (B)).
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up, and the median time to dose reduction was 12 months 
(range, 0.2-63).
Finally, 18 patients (23%) permanently 
discontinued treatment: of these, 10 for toxicity, 5 
for treatment failure, 2 because of their accrual into 
suspension trials, and one for personal decision. The 
median time to discontinuation was 43.5 months (range, 
10.6 - 90.8).
Table 3: Adverse reactions associated with nilotinib administration (graded according to CTC-AE grading system) 
and time intervals to events
TOXICITY n (%)
Every toxicity
 Yes 45 (58%)
 No 33 (42%)
Hematological toxicity 10 (13%)
 Grade 1-2 10 (100%)
 Grade 3 0
 Grade 4 0
Type of hematological toxicity
 Trombocytopenia 2
 Neutropenia 2
 Anemia 6
Time to hematological toxicity (months)* 1.3 (1-12)
Extra-hematological toxicity 35 (45%)
 Grade 1-2 17 (48%)
 Grade 3 16 (46%)
 Grade 4 2 (6%)
Type of extra-hematological toxicity
 Skin toxicity (rash, dry skin, erythema – grade 3, 3 pts) 8
 Increase in transaminases (grade 3 in 5 pts), bilirubin (grade 3 in 2 pt) 8
 Increase in amylase/lipase (grade 3 in 4 pts) 8
 Increase in serum glucose/cholesterol 3
 Ocular toxicity (hemorrhage, dry eye, conjunctivitis – grade 3 in 2 pts) 3
 Cardio-vascular toxicity (PAOD – grade 4, hypertension) 3
 CNS toxicity (migrain, stroke – grade 4) 2
Time to extra-hematological toxicity (months)* 7.5 (0.2-85)
Dose reduction
 Yes 39 (50%)
 No 39 (50%)
Time to dose reduction (months)* 12 (0.2-63)
Nilotinib definitive discontinuation
 Yes 18 (23%)
 No 60 (77%)
Notes: *, values are expressed as median (min-max range)
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Transporters’ polymorphisms and their clinical 
significance
Because genetic polymorphisms of hOCT1 and 
ABCB1 are associated with variable influx/efflux activity 
of transporters, the following polymorphisms were 
evaluated by quantitative PCR: c.480C>G [hOCT1]; 
c.1236C>T, c.2677G>T and c.3435C>T [ABCB1]. In 
particular, minor allele frequencies (MAFs) for the 
investigated polymorphisms were comprised in the range 
0.207-0.500, and the Hardy-Weinberg equilibrium (HWE) 
was demonstrated for all single nucleotide polymorphisms 
(SNPs; Table 4).
The ABCB1 loci were in linkage disequilibrium 
(range D’=0.486-0.944), and frequencies of the 
corresponding haplotypes are reported in Table 5. 
Interestingly, only 14.2% of patients were homozygous for 
the wild-type haplotype (haplotype 1), while 33.3% were 
homozygous for the polymorphic haplotypes (haplotypes 
2-7).
The ABCB1 [c.1236C>T] did not influence the 
probability of achieving CCyR, EMR, MR3, or DMR 
or the time to CCyR, MR3, or DMR. The same lack of 
significance on magnitude or time to responses was found 
for ABCB1 [c.2677G>T] polymorphism.
On the contrary, the DMR rate was significantly 
higher for polymorphic c.3435CT/TT patients than for the 
wild-type c.3435CC ones (77.8% vs 43.0%; p=0.02).
Although single ABCB1 polymorphisms returned 
different results when compared with clinical endpoints, 
ABCB1 haplotypes were investigated for possible 
associations with nilotinib efficacy and/or tolerability. 
The comparisons were made between wild-type (i.e., 
CC/GG/CC) and polymorphic haplotypes (any of the 
other combinations that included polymorphic alleles). 
In agreement with the results presented above, ABCB1 
haplotypes did not significantly condition either the CCyR 
and MR rate or the time to achieve MR3 or DMR.
Similar findings were obtained for hOCT1, whose 
genotype at locus c.480 did not exert any influence on 
CCyR, EMR, MR3 or DMR achievement, or on the time 
to achieve MR3 or DMR.
Finally, the ABCB1 polymorphisms did not 
significantly condition the EFS (Figure 2), the presence of 
toxicities nor their grade, either when analyzed alone or as 
haplotypes. The same findings were obtained for hOCT1 
genotypes with respect to the c.480C>G polymorphism.
DISCUSSION
The present study suggests that ABCB1 and hOCT1 
transmembrane transporters have not a significant impact 
on the efficacy and tolerability of nilotinib when used as 
a first treatment for CML patients. Indeed, our findings 
clearly show that polymorphisms associated with an 
altered activity of these transporters do not predict either 
the clinical outcome or the tolerability. Consequently, we 
believe that these results could have a clinical output, 
supporting the use of nilotinib regardless the genetic status 
of patients with respect of the two considered transporters.
Although the advent of imatinib has dramatically 
improved the prognosis of CML, about 30% of patients 
suspend the therapy for poor efficacy or adverse events 
[27]. More recently, second-generation (dasatinib, 
nilotinib, bosutinib) and third-generation TKIs (ponatinib) 
partially overcame those issues, making possible the 
successful treatment of resistant/intolerant patients, too 
[28, 29]. The choice of the TKI (imatinib, dasatinib or 
Table 4: Distribution of allele frequencies for investigated polymorphic loci in ABCB1 and hOCT1 genes. For c.2677 
locus the T/A alleles are indicated as W
Gene and SNP Genotype Frequency % Allele Frequency % HWE
ABCB1 c.1236C>T CC 36.0 C
T
59.3
40.7
χ2: 0.082
p=0.775CT 46.7
TT 17.3
ABCB1 c.2677G>W GG 40.5 G
T
64.3
35.7
χ2: 0.058
p=0.810GW 47.6
WW 11.9
ABCB1 c.3435C>T CC 24.0 C
T
50.0
50.0
χ2: 0.120
p=0.729CT 52.0
TT 24.0
hOCT1 c.480C>G CC 64.0 C
G
79.3
20.7
χ2: 0.315
p=0.575CG 30.7
GG 5.3
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nilotinib) as a first-line therapy is sometimes difficult. 
Generally, the decision is led by the risk score assessment 
(second-generation TKIs for higher risk scores), age 
(imatinib for older people), co-morbidities (imatinib 
or dasatinib for patients with previous cardio-vascular 
events, nilotinib for those with lung diseases or pulmonary 
hypertension), but no clear suggestions came from the 
available international guidelines. Therefore, a careful 
choice of the best TKI ab initio is crucial to reach optimal 
responses and to reduce the occurrence of adverse events, 
hence promoting patient’s adherence to treatment.
Several attempts to personalize treatment 
have been made evaluating the predictive role of the 
polymorphisms in genes coding for transmembrane 
Table 5: Distribution of ABCB1 haplotypes (c.1236-c.2677-c.3435) inferred from genotypes of the enrolled patients. 
For c.2677 locus the T/A alleles are indicated as W
[Hapl. ID] Haplotype definition Observed frequency
1 CGC 0.383
[2] CGT 0.224
[3] TWT 0.286
[4] TGT 0.014
[5] TGC 0.023
[6] TWC 0.059
[7] CWC 0.012
Figure 2: The probability of event-free survival (EFS) according to the ABCB1 polymorphisms (panels A and B) and the hOCT1 
polymorphism (panel C).
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transporters. If the picture is clear for imatinib, which is 
a substrate of both influx (hOCT1) and efflux (ABCB1) 
transporters, many doubts and contrasting findings 
characterize second- and third-generation TKIs. For 
example, the efflux of nilotinib, dasatinib and ponatinib 
was not significantly influenced by the expression of 
wild-type or polymorphic ABCB1 in HEK293 and K562 
cell lines, differently from imatinib [24]. On the contrary, 
other authors demonstrated that imatinib, dasatinib, 
nilotinib were all substrates of ABCB1 in the same K562 
cells [25]. Because ABCB1 over-expression significantly 
reduced when cells were continuously exposed to 
nilotinib, the authors hypothesized that the entity of the 
transporter gene expression would be important in the 
early stages of resistance to TKIs only [30]. Moving 
from the in vitro models to the clinical setting, other 
authors showed that the ABCB1 wild-type haplotypes 
(at positions c.1236, c.2677 and c.3435) were associated 
with a significantly lower MR3 rate (50% vs 93%) under 
treatment with TKIs. In that small series, only 6 patients 
received nilotinib, 2 subjects carrying the wild-type and 
4 the heterozygous polymorphic haplotype. In contrast 
with patients receiving imatinib, all cases treated with 
nilotinib achieved the MR3, regardless their haplotype 
[31]. The samples size of that study with respect to 
nilotinib was very limited, but our study showed the 
same results in a larger group of patients: the wild-type 
or polymorphic haplotypes did not impact either on the 
quality of response (CCyR, EMR, MR3, DMR) or on 
the EFS.
In agreement with what observed for ABCB1, we did 
not find any clinical impact for the hOCT1 polymorphism 
on nilotinib efficacy and tolerability; this result was 
already expected, because it is well known that nilotinib 
is more lipophilic than imatinib and in vitro experiments 
suggested that it is not substrate for the hOCT1 influx 
transporter [32]. Other studies investigated the substrate 
affinity of nilotinib for other transmembrane transporters, 
but conclusive results are not yet achieved [33]. The 
lack of any significant effect of hOCT1 and ABCB1 
polymorphisms on the achievement of cytogenetic and 
molecular responses or on the EFS could be particularly 
relevant in the clinical practice. Indeed, if a patient carries 
the hOCT1 polymorphic allele, for example, we can 
suppose that he will have a higher probability of failure 
and higher toxicity when exposed to imatinib [17]. In this 
case, a second-generation TKI, such as nilotinib, might 
represent a valid option for optimizing the efficacy and 
reducing the occurrence of AEs.
On the other hand, when patients receive imatinib, 
it has been reported a higher molecular response rate in 
the cohort of cases with polymorphic ABCB1 [34]; in our 
series, ABCB1 polymorphisms did not condition the time 
to response, its magnitude or the EFS, thus supporting the 
use of nilotinib independently from the genetic variants of 
the membrane transporters.
Moreover, our series of patients is really 
representative of the real clinical practice as witnessed 
by the superimposable rates of cytogenetic and molecular 
responses between our study and the ENESTnd trial. 
Indeed, in that international trial, the CCyR rate was 
80%, and 77.2% of patients achieved an MR3 [4]. In line 
with those results, the CCyR rate was 88% in our study, 
and 77% of patients achieved an MR3. Furthermore, the 
5-year EFS in our series was lower than that observed 
in the ENESTnd trial (81% vs 95%, respectively). That 
difference could depend on the wider definition of EFS 
in our study, because we considered the loss of MR3 and 
nilotinib discontinuation for any cause. Indeed, when 
the same ENESTnd criteria were applied to our series, 
the 5-year EFS would increase to 94.5%, the same EFS 
observed in the ENESTnd trial.
Finally, the overall AEs in our study were less 
frequent than in the ENESTnd trial (41% vs 60%); we 
can suppose that this discrepancy could depend on the 
prolonged experience in the drug management in our 
series in respect of the pivotal trial. Nevertheless, the 
occurrence of the cardiovascular events was similar (8% 
in the ENESTnd vs 7.5% in our series). Interestingly, 
in another Italian multicenter “real-life” study on 110 
patients, 27% of them experienced cardiovascular events 
when nilotinib was administered as second-line treatment 
[35]. That comparison further strengthens the better 
tolerability of nilotinib as upfront therapy, despite our 
study recorded a slight higher discontinuation rate with 
respect to that reported in the ENESTnd trial (3.8% vs 
2.5%, respectively).
It is worth to note that the demonstrated lack of 
any significant association between gene polymorphisms 
of transmembrane transporters and clinical outcome has 
been found in a homogenous cohort of patients: the fact 
that all cases received nilotinib as first-line treatment 
eliminates the possible “contaminating” effects induced by 
previously used TKIs. Nevertheless, some characteristics 
of our study have to be considered: first of all, clinical 
records were available for all patients and they gave the 
possibility to exclude the risk of drug-drug interactions, 
as well as smoke, alcohol consumption and comorbidities. 
On the contrary, the influence of dietary and herbal factors 
could not be ruled out in a complete manner. Moreover, 
other patients’ characteristics, such as physiological 
(body mass index, renal and liver function), pathological 
(comorbidities), genetic (gene polymorphisms, mutations) 
and epigenetic factors (changes in gene expression) may 
significantly have an influence on the clinical outcome 
during nilotinib administration [36]. Although some of 
those factors have been ruled out thanks to our clinical 
records, other ones remain unexplored and their future 
evaluation will require a wider enrollment, further efforts, 
and probably different analytical platforms, as well as 
genome sequencing (i.e., next generation sequencing 
or whole genome association studies). Moreover, our 
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database included patients enrolled in retrospective 
and prospective cohorts, but, as stated above, the strict 
adoption of the 2013 ELN guidelines for all patients 
minimized the risk of potential biases. Finally, the present 
clinical findings are similar or superimposable with 
those reported in the ENESTnd trial as stated above, 
thus strengthening the reliability of our spontaneous and 
cooperative study.
In conclusion, for the first time our study 
supports the use of nilotinib as first-line treatment in a 
homogeneous series of CML patients irrespective to the 
hOCT1 and ABCB1 genotypes, replicating data obtained in 
the largest, company-driven ENESTnd trial. In contrast to 
these findings, our group recently published the significant 
influence of ABCB1/hOCT1 combined genotype on 
imatinib efficacy and tolerability [37]. Therefore, a 
simple and cheap test, such as a quantitative PCR, would 
aid the physician to correctly choose the right TKI for 
each patient, even if the test could not be available for all 
patients. Indeed, when a reduced cellular uptake through 
hOCT1 and higher efflux by ABCB1 do increase the risk 
of imatinib failure, nilotinib may represent the optimal 
choice.
MATERIALS AND METHODS
The current study is part of a spontaneous, not 
sponsored sub-study of the “TIKLET” trial (Tyrosine 
Kinase Inhibitors in chronic myeloid leukemia: 
Efficacy and Tolerability; ClinicalTrials.gov identifier: 
NCT01860456), which has been carried out on 78 adult 
subjects affected by CML in chronic phase receiving 
nilotinib 600 mg as first-line treatment, outside clinical 
trials, in 8 Italian Hematology Divisions. Of note, none of 
the enrolled patients took part in previous clinical trials.
From January 2013 to July 2015, 29 patients were 
prospectively enrolled in the study. Sample size analysis 
demonstrated the study was downsized, hence further 
49 subjects receiving first-line nilotinib after 2008 were 
also considered if a) they received nilotinib as first-line 
treatment and b) the standardized BCR-ABL1/ABL1 
quantitative PCR was available, according to the Labnet 
Italian Network standardized operative procedures. 
Those criteria allowed the complete revision of patients’ 
clinical history and laboratory results (see following 
paragraphs), hence statistical analyses were performed 
in a homogeneous population with respect to clinical and 
molecular endpoints. Statistical analyses between groups 
were performed only to exclude severe differences.
The study protocol has been approved by the Ethics 
Committee of the Azienda Ospedaliero Universitaria 
Pisana (protocol n. 46013/2011) and by local Ethics 
Committees of participating centres. Patients gave their 
informed consent to study participation before their 
enrollment.
The following inclusion criteria were adopted: (a) 
patients of both gender, (b) aged ≥18 years, (c) treated 
with nilotinib as first-line treatment, (d) with at least 3 
months of follow-up, (e) the availability of standardized 
BCR-ABL1/ABL1 quantitative PCR results both at 
diagnosis and during the follow-up; (f) complete clinical 
history of patients.
All patients were treated with an initial daily dose 
of 600 mg.
Age, sex, Sokal, Hasford and EUTOS risk scores 
were recorded; for each patient, two independent 
hematologists scored the hematological, cytogenetic 
and molecular responses defined according to the ELN 
recommendations edited in 2013 [26]. In this manner, 
every bias in scoring the clinical efficacy of nilotinib was 
kept at a minimum (see below).
The AEs data collection has been done according 
to the Common Toxicity Criteria –Adverse Events (CTC-
AE) version 4.03. In agreement with the efficacy data, 
the database of toxicities was deeply reviewed by two 
hematologists according to the above-cited CTC-AE 
criteria.
BCR-ABL1/ABL1 response monitoring
Hematological, cytogenetic, and molecular 
responses were assessed and classified according to 
the ELN guidelines [26]. Furthermore, molecular 
monitoring was carried out on peripheral blood samples 
and performed by quantitative PCR, as established by the 
European guidelines [38] applied by all Italian laboratories 
afferent to the LABNET network, and results expressed 
in accordance with the International Scale (IS). In 
particular, molecular responses were “graded” according 
to the logarithmic reduction with respect to a basal level 
(considered as 100%). Thus, the molecular responses 
MR3, MR4 and MR5 imply 3-log (0.1% IS), 4-log (0.01% 
IS) and 5–log (0.001% IS) reduction, respectively. The 
responses with a ≥4-log decrease identified the DMR, 
the sensitivity of assays depending on the number of the 
ABL1 copies in each amplification well (always >10.000). 
Finally, the EMR was defined as a BCR-ABL1/ABL1 %IS 
≤10% at 3 months from the treatment beginning.
Pharmacogenetic analysis
The genetic variables considered were represented 
by the following polymorphisms: a) hOCT1 rs683369 
[c.480C>G]; b) ABCB1 rs1128503 [c.1236C>T] (exon 
12); c) ABCB1 rs2032582 [c.2677G>T/A] (exon 21); d) 
ABCB1 rs1045642 [c.3435C>T] (exon 26).
Genomic DNA extracted from peripheral blood 
(QIAamp DNA Blood Mini Kit, Qiagen, Milan, Italy) 
was used to obtain the genotype of each patient by using 
specific TaqMan assays (Life Sciences, Milan, Italy) on 
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an ABI Prism 7900HT Sequence Detection System (Life 
Sciences).
MAF calculation, HWE evaluation and haplotype 
analyses were performed by using Arlequin software 
[39]. The recessive model was adopted, grouping patients 
according to the absence (wild-type) or the presence 
(heterozygous or polymorphic homozygous) of at least 
one polymorphic allele for each locus.
Statistical analysis
The diagnoses and the corresponding follow-
up periods for the retrospective cohort were reviewed 
independently by two hematologists, according to the 
new ELN recommendations [26]. That approach gave the 
possibility to gather together clinical records from both 
retrospective and prospective cohort of patients, without 
increasing the risk of potential biases.
For the main clinical variables, central indices 
(mean, median) and dispersion parameters (SD, range) 
were obtained. The analysis of variance (ANOVA) was 
used to evaluate every possible association between 
clinical efficacy measures and genetic variables. The 
Fisher’s exact test was applied for the analysis of discrete 
variables, while the t-test was used for comparing the time 
to cytogenetic or molecular response and dichotomous 
variables.
The EFS was assessed from the date of initiation 
of treatment to the onset of any of the following events: 
absence of CCyR at 12 months, loss of CCyR and MR3 
at any time during treatment, withdrawal of the drug for 
toxicity, progression to the accelerated/blast phase, any 
cause of death during the study. The probability of EFS 
was calculated using the Kaplan-Meier method.
Overall, the level of significance was set at p<0.05.
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